Ghent University Academic Bibliography

Advanced

Nasal IL-5 levels determine the response to anti-IL-5 treatment in patients with nasal polyps

Philippe Gevaert UGent, Doris Lang-Loidolt, Andreas Lackner, Heinz Stammberger, Heribert Staudinger, Thibaut Van Zele UGent, Gabriële Holtappels UGent, Jan Tavernier UGent, Paul Van Cauwenberge UGent and Claus Bachert UGent (2006) JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY. 118(5). p.1133-1141
abstract
Background: Chronic rhinosinusitis with nasal polyps is characterized by an eosinophilic inflammation and high IL-5 levels. Objectives: Antagonizing the effect of IL-5 is a potential new treatment strategy in patients with nasal polyps. Methods: In a double-blind, placebo-controlled, randomized, 2-center safety and pharmacokinetic study, 24 subjects with bilateral nasal polyps were randomized to receive a single intravenous infusion of reslizumab, a humanized anti-human IL-5 mAb, at 3 mg/kg or 1 mg/kg or placebo. We evaluated the safety and pharmacokinetics of reslizumab, and biologic activity was assessed by means of endoscopic evaluation of polyp size, symptoms, peripheral eosinophil counts, peripheral and local IL-5 levels, eotaxin levels, and eosinophil cationic protein levels. Results: We demonstrated that a single injection of reslizumab up to 3 mg/kg is safe and well tolerated. Blood eosinophil numbers and concentrations of eosinophil cationic protein were reduced up to 8 weeks after treatment in serum and nasal secretions. Individual nasal polyp scores improved only in half of the treated patients for 4 weeks. Responders had increased IL-5 concentrations in nasal secretions at baseline compared with nonresponders, and logistic regression analysis revealed that increased nasal IL-5 levels (> 40 pg/mL) predict the response to anti-IL-5 treatment. Conclusion: A single injection of anti-IL-5 reduces the size of nasal polyps for 4 weeks in half of the patients, and nasal IL-5 levels predict the response to anti-IL-5 treatment. Clinical implications: Intravenous administration of a humanized anti-human IL-5 mAb is safe and reduces the size of nasal polyps in half of the patients.
Please use this url to cite or link to this publication:
author
organization
year
type
journalArticle (original)
publication status
published
subject
keyword
HYPERREACTIVITY, anti-IL-5, INDUCED AIRWAY HYPERRESPONSIVENESS, HUMAN INTERLEUKIN-5 RECEPTOR, ANTI-INTERLEUKIN-5 ANTIBODY, DECREASED EXPRESSION, HUMAN EOSINOPHILS, ALPHA EXPRESSION, ASTHMA, MEMBRANE, CYTOKINES, IL-5 receptor alpha, IL-5, eosinphils, nasal polyps, chronic rhinosinusitis
journal title
JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY
J. Allergy Clin. Immunol.
volume
118
issue
5
pages
1133 - 1141
Web of Science type
Article
Web of Science id
000244282300020
JCR category
ALLERGY
JCR impact factor
8.829 (2006)
JCR rank
1/16 (2006)
JCR quartile
1 (2006)
ISSN
0091-6749
DOI
10.1016/j.jaci.2006.05.031
language
English
UGent publication?
yes
classification
A1
copyright statement
I have transferred the copyright for this publication to the publisher
id
360715
handle
http://hdl.handle.net/1854/LU-360715
date created
2007-03-30 11:10:00
date last changed
2015-06-17 10:40:31
@article{360715,
  abstract     = {Background: Chronic rhinosinusitis with nasal polyps is characterized by an eosinophilic inflammation and high IL-5 levels. 
Objectives: Antagonizing the effect of IL-5 is a potential new treatment strategy in patients with nasal polyps. 
Methods: In a double-blind, placebo-controlled, randomized, 2-center safety and pharmacokinetic study, 24 subjects with bilateral nasal polyps were randomized to receive a single intravenous infusion of reslizumab, a humanized anti-human IL-5 mAb, at 3 mg/kg or 1 mg/kg or placebo. We evaluated the safety and pharmacokinetics of reslizumab, and biologic activity was assessed by means of endoscopic evaluation of polyp size, symptoms, peripheral eosinophil counts, peripheral and local IL-5 levels, eotaxin levels, and eosinophil cationic protein levels. 
Results: We demonstrated that a single injection of reslizumab up to 3 mg/kg is safe and well tolerated. Blood eosinophil numbers and concentrations of eosinophil cationic protein were reduced up to 8 weeks after treatment in serum and nasal secretions. Individual nasal polyp scores improved only in half of the treated patients for 4 weeks. Responders had increased IL-5 concentrations in nasal secretions at baseline compared with nonresponders, and logistic regression analysis revealed that increased nasal IL-5 levels ({\textrangle} 40 pg/mL) predict the response to anti-IL-5 treatment. 
Conclusion: A single injection of anti-IL-5 reduces the size of nasal polyps for 4 weeks in half of the patients, and nasal IL-5 levels predict the response to anti-IL-5 treatment. 
Clinical implications: Intravenous administration of a humanized anti-human IL-5 mAb is safe and reduces the size of nasal polyps in half of the patients.},
  author       = {Gevaert, Philippe and Lang-Loidolt, Doris and Lackner, Andreas and Stammberger, Heinz and Staudinger, Heribert and Van Zele, Thibaut and Holtappels, Gabri{\"e}le and Tavernier, Jan and Van Cauwenberge, Paul and Bachert, Claus},
  issn         = {0091-6749},
  journal      = {JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY},
  keyword      = {HYPERREACTIVITY,anti-IL-5,INDUCED AIRWAY HYPERRESPONSIVENESS,HUMAN INTERLEUKIN-5 RECEPTOR,ANTI-INTERLEUKIN-5 ANTIBODY,DECREASED EXPRESSION,HUMAN EOSINOPHILS,ALPHA EXPRESSION,ASTHMA,MEMBRANE,CYTOKINES,IL-5 receptor alpha,IL-5,eosinphils,nasal polyps,chronic rhinosinusitis},
  language     = {eng},
  number       = {5},
  pages        = {1133--1141},
  title        = {Nasal IL-5 levels determine the response to anti-IL-5 treatment in patients with nasal polyps},
  url          = {http://dx.doi.org/10.1016/j.jaci.2006.05.031},
  volume       = {118},
  year         = {2006},
}

Chicago
Gevaert, Philippe, Doris Lang-Loidolt, Andreas Lackner, Heinz Stammberger, Heribert Staudinger, Thibaut Van Zele, Gabriële Holtappels, Jan Tavernier, Paul Van Cauwenberge, and Claus Bachert. 2006. “Nasal IL-5 Levels Determine the Response to anti-IL-5 Treatment in Patients with Nasal Polyps.” Journal of Allergy and Clinical Immunology 118 (5): 1133–1141.
APA
Gevaert, Philippe, Lang-Loidolt, D., Lackner, A., Stammberger, H., Staudinger, H., Van Zele, T., Holtappels, G., et al. (2006). Nasal IL-5 levels determine the response to anti-IL-5 treatment in patients with nasal polyps. JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY, 118(5), 1133–1141.
Vancouver
1.
Gevaert P, Lang-Loidolt D, Lackner A, Stammberger H, Staudinger H, Van Zele T, et al. Nasal IL-5 levels determine the response to anti-IL-5 treatment in patients with nasal polyps. JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY. 2006;118(5):1133–41.
MLA
Gevaert, Philippe, Doris Lang-Loidolt, Andreas Lackner, et al. “Nasal IL-5 Levels Determine the Response to anti-IL-5 Treatment in Patients with Nasal Polyps.” JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY 118.5 (2006): 1133–1141. Print.